E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Hun Ju Lee,Hagop M. Kantarjian,Deborah A. Thomas,Stefan Faderl,Charles Koller,Alessandra Ferrajoli,Elias Jabbour,Rebecca Garris,Partow Kebriaei,Richard E. Champlin,Gautam Borthakur,William G. Wierda,Jan A. Burger,Jorge E. Cortes,Susan O'Brien,Farhad Ravandi +15 more
TL;DR: The introduction of tyrosine Kinase Inhibitors (TKI) has significantly improved the outcome of patients (pts) with Ph+ ALL and Dasatinib (Db) is a second generation dual SRC/ABL TKI with greater potency compared to Imatinib in inhibiting BCR/abL.
Journal ArticleDOI
Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia
Iman Aboudalle,Hagop M. Kantarjian,Nicholas J. Short,Farhad Ravandi,Koji Sasaki,Guillermo Garcia-Manero,Guillermo Montalban-Bravo,Jorge E. Cortes,Christopher B. Benton,Ghayas C. Issa,Maria Khouri,Patrice Nasnas,Susan O'Brien,Susan O'Brien,Elias Jabbour +14 more
TL;DR: Binatumomab, a bispecific T-cell engager (BiTe) CD3-CD19 antibody, showed improved overall survival compared to standard chemotherapy and was well tolerated with most adverse events being transient.
Journal ArticleDOI
Results of Off-Label Venetoclax Use in Combination with Low-Intensity Chemotherapy in Patients with Relapsed and Refractory Myeloid Malignancies
Caitlin R. Rausch,Courtney D. DiNardo,Tapan M. Kadia,Koichi Takahashi,Nitin Jain,Christopher B. Benton,Philip A. Thompson,Maro Ohanian,Wendy Covert,Morgan Mace,Kayleigh Marx,Naveen Pemmaraju,Naval Daver,Elias Jabbour,Jorge E. Cortes,Guillermo Garcia-Manero,Farhad Ravandi,Marina Konopleva,Hagop M. Kantarjian +18 more
TL;DR: Venetoclax (VEN), a selective BCL2 inhibitor, has demonstrated single-agent activity in patients with relapsed and refractory acute myeloid leukemia (AML) and encouraging safety and efficacy has also been established with the combination of VEN and the hypomethylating agents (HMA), as well as low-dose cytarabine (LDAC) (NCT02287233).
Journal ArticleDOI
Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
Elias Jabbour,Naval Daver,Tina Dong,Tapan M. Kadia,Susan O'Brien,Jorge E. Cortes,Farhad Ravandi,Naveen Pemmaraju,Hady Ghanem,Stefan Faderl,Gautam Borthakur,Hagop M. Kantarjian,Guillermo Garcia-Manero +12 more
TL;DR: In the largest cohort of lower risk MDS pts treated with HMA, the outcome after HMA failure is poor and treatment of those patients remains an unmet medical need.
Journal ArticleDOI
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.
Rashmi Kanagal-Shamanna,Guillermo Montalban-Bravo,Panagiotis Katsonis,Koji Sasaki,Caleb A. Class,Elias Jabbour,David A. Sallman,Anthony M. Hunter,Christopher B. Benton,Kelly S. Chien,Rajyalakshmi Luthra,Carlos E. Bueso-Ramos,Tapan M. Kadia,Michael Andreeff,Rami S. Komrokji,Najla Al Ali,Nicholas J. Short,Naval Daver,Mark J. Routbort,Joseph D. Khoury,Keyur P. Patel,Irene Ganan-Gomez,Yue Wei,Gautam Borthakur,Farhad Ravandi,Kim Anh Do,Kelly A. Soltysiak,Olivier Lichtarge,L. Jeffrey Medeiros,Hagop M. Kantarjian,Guillermo Garcia-Manero +30 more